Biotron Limited · ASX:BIT
Biotron — Investor Presentation (October 2023)
14 slides from Biotron's investor presentation, Oct 24, 2023
Slide 1: Presentation to Investors (ASX cover letter)
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 24 October 2023 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (14 pages by email) For personal use only Dear Madam PRESENTATION T
Slide 2: Biotron Limited (ASX:BIT) October 2023
BIOTRON LIMITED For personal use only (ASX:BIT) October 2023
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These state
Slide 4: Industry-leading experts focused on transformative treatments for viral diseases
Industry-leading experts focused on transformative treatments for viral diseases • Experienced Board and management team with pharma, financial and VC backgrounds For personal use only • Clinical stage company with portfolio of small molecule drugs targeting viral diseases with major health problems
Slide 5: Near-term value creation milestones anticipated in late 2023
Near-term value creation milestones anticipated in late 2023 • The headline results from three human Phase 2 clinical trials are expected in coming weeks For personal use only • Two HIV-1 Phase 2 trials and a SARS-CoV-2/COVID-19 Phase 2 trial • All three trials have been completed i.e. all patients
Slide 6: Financial Information
Financial Information Key Financial Metrics Ticker Code ASX: BIT For personal use only Share Price (19/10/2023) A $0.088 Market Cap A $77 million 12 Month Trading Range A $0.024 – 0.115 BITOC 25/11/24 $0.06 listed options A $0.055 (19 Oct) Cash Position (06/2023) A $3.98 million Top 20 shareholders
Slide 7: Portfolio of Clinical and Preclinical Assets
Portfolio of Clinical and Preclinical Assets RESEARCH DEVELOPMENT For personal use only DISCOVERY/LEAD INDICATION COMPOUND IND ENABLING/ PRECLINICAL PHASE 1 PHASE 2 PHASE 3 OPTIMISATION HIV-1 BIT225 * HIV-1 Next generation COVID-19 BIT225 * COVID-19 Next generation HBV Lead Optimisation Dengue, Infl
Slide 8: Recent Milestones & Achievements
Recent Milestones & Achievements • Completed enrolment of two Phase 2 HIV-1 clinical trials that build on positive results in previous clinical For personal use only studies • Completed enrolment of Phase 2 COVID-19 clinical trial • Based on demonstration that BIT225 prevents development of COVID-19
Slide 9: COVID-19 Clinical Program
COVID-19 Clinical Program • In 2022 Biotron’s lead antiviral drug BIT225 was shown to: WHY COVID? • Prevent COVID-19, For personal use only • Some vulnerable populations remain at risk • Reduce virus levels, and • Current drugs have limitations due to • Stop the cytokine storm in a relevant, robust,
Slide 10: BIT225 Prevents COVID-19 in Animal Model of Disease
BIT225 Prevents COVID-19 in Animal Model of Disease Twelve-day treatment of SARS-CoV-2 infected K18-hACE2 mice with BIT225. (A) Dosing Scheme. For personal use only (B) Kaplan-Meier plot: vehicle control (black line, n = 7, 0% survival); BIT225 12-day treatment group (blue line, n = 7, 100% survival
Slide 11: HIV-1 Clinical Program
HIV-1 Clinical Program Why HIV-1? • Two Phase 2 HIV-1 clinical trials recently completed at sites in Sydney, Australia • Despite antiretroviral drugs (ART) over 38.4 million people (Holdsworth House, East Sydney Doctors and St Vincent’s Hospital, Darlinghurst) For personal use only globally are livi
Slide 12: Unlocking value for other viral targets
Unlocking value for other viral targets • Post pandemic there is an international focus on preparedness for future viral outbreaks For personal use only • Small molecule drugs are essential to beating the next pandemic • The threat of emerging pandemics is real, especially for coronavirus and other
Slide 13: BIT225 Opportunity Summary
BIT225 Opportunity Summary • BIT225 is a very important clinical asset for Biotron For personal use only • Previous positive clinical trial data have significantly de-risked the program • Clear clinical development program designed to demonstrate to regulators and pharma how the drug may be used to
Slide 14: Biotron Limited contact
BIOTRON LIMITED For personal use only (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329